Monthly Archives: January 2018

Many factors about low bone mineral density (BMD) in patients with inflammatory bowel disease (IBD) have been reported. Continue reading →

IBD therapeutic endpoints have evolved over time with the addition of mucosal healing (MH) as a treatment goal. Adult data suggest patients who achieve MH have improved outcomes but pediatric data is lacking. The aims of our study was to evaluate the r… Continue reading →

Vedolizumab (VDZ) and infliximab (IFX) are both approved as first line induction agents in moderately to severely active UC. However, there are no head-to-head studies comparing the relative effectiveness of the two. Here we provide a real-world compar… Continue reading →

Perianal disease including perianal fistula and perianal abscess is known as one of the poor prognostic factors of Crohn’s disease (CD). However, there has been no tool for CD patients to check their perianal symptoms. We aimed to develop self-screen… Continue reading →

Infliximab and vedolizumab infusions pose a burden to inflammatory bowel disease (IBD) patients due to the need to travel and take time from work. To minimize burden, home infusions are available for selected patients. We aimed to describe the populati… Continue reading →

Treatments for Crohn’s disease (CD) or ulcerative colitis (UC) include anti-TNFs and novel therapies, but optimal real-world treatment sequencing has not been well-studied. This study compared healthcare resource use (HRU) and costs associated with s… Continue reading →

Rates of surgical recurrence after curative intestinal resection for Crohn’s disease are high. It is unclear whether early initiation of postoperative prophylaxis is efficacious in preventing surgical recurrence. Continue reading →

Antibiotics have been used to treat luminal Crohn’s disease (CD) with variable success. Rifaximin has a favorable safety profile given its limited systemic absorption. Studies suggest clinical improvement in patients with mild-moderate CD treated wit… Continue reading →

As inflammatory bowel disease (IBD) patients are at risk for low bone mineral density (BMD), we sought to evaluate: 1) the utility of biomechanical CT analysis (BCTA) in assessing bone strength and BMD in IBD patients, 2) Cornerstone guideline utility … Continue reading →

Among hospitalized pediatric inflammatory bowel disease (IBD) patients, the decision to initiate parenteral nutrition (PN) involves balancing the nutritional benefits against the risks of infectious and thrombotic complications. However, the absolute r… Continue reading →